



ASX Announcement

23 May 2025

Change of Address

Sydney, Australia; 23 May 2025: Cambium Bio Limited (ASX:CMB) (**Cambium Bio, Cambium or Company**), a clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue repair applications, today announces that in accordance with Listing Rule 3.14, effective immediately, the Company's Registered Office and Principal Place of Business Address has changed to **Unit 2.06/31 Lexington Dr, Bella Vista, NSW 2153**.

This announcement was authorised by the Company Secretary of Cambium Bio Limited.

- END -

About Cambium Bio Limited

Cambium Bio Limited (ASX:CMB) is a Sydney-based clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue repair applications. The Company's proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. Cambium Bio's lead product candidate, Elate Ocular®, is being developed to address significant unmet medical needs in the treatment of dry eye disease. In addition, the Company's stem cell platform, Progenza™, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications. Cambium Bio is committed to advancing its pipeline through clinical development and commercialization, with the goal of providing transformative treatments to improve patient outcomes. For more information about the Company and its programs, please visit www.cambium.bio

For further information, please contact:

Cambium Bio Limited
Unit 2.06/31 Lexington Dr, Bella Vista, NSW 2153, Australia
ABN 13 127 035 358
Phone: 1300 995 098
www.cambium.bio